Gérald Ulrich

Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France.

Laboratoire Cerba SA provides medical research services. It conducts tests in the fields of virology, autoimmune disease, allergy, endocrinology, oncology, toxicology and molecular genomics. The company was founded in 1967 and is headquartered in Saint-Ouen-l'Aumône, France.

Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France.